Dysuria in a young man is categorically different from dysuria in a woman — UTI in younger men is less common, and when it does occur, it should prompt consideration of a structural cause (urethral stricture, BPH in older men, prostatitis, reflux) or an STI. A recognised pitfall is prescribing nitrofurantoin or trimethoprim for 'UTI' in a sexually active young man without performing an STI screen — this misses gonorrhoea or Chlamydia, delays appropriate STI treatment, misses partner notification, and may provide partial cover for GC that selects for resistance. Ask sensitively about sexual exposure and perform STI NAAT (first-void urine) when urethritis or sexual exposure is plausible; send a pre-treatment MSU in men with suspected lower UTI. Do not delay treatment of a suspected bacterial UTI or prostatitis while awaiting STI results. UTI in men requires 7-day treatment (not 3 days) because of the risk of subclinical prostatic involvement.

The differentiation between UTI and urethritis is a clinically important distinction that determines whether the patient needs antibiotics, STI screening, or both. The key clinical discriminators: UTI produces a symptom triad of dysuria + frequency + urgency (the bladder is inflamed and contracting against urine), while urethritis produces predominantly dysuria (the urethra is inflamed) without significant frequency/urgency. Urethral discharge strongly suggests urethritis. The urine dipstick is unhelpful in differentiating the two conditions — leucocytes are positive in both UTI (inflammatory cells in bladder urine) and urethritis (inflammatory cells in urethra contaminate the urine sample). MSU culture helps, but a negative culture may reflect prior antibiotics, low bacterial count, sampling problems, fastidious organisms, vaginitis, urethritis or non-infective disease. A patient with dysuria and a positive dipstick but a negative MSU culture should be considered for Chlamydia/GC testing according to sexual risk.

The nitrofurantoin and MSU before prescribing principle is set out in NICE NG109 and the UKHSA diagnostic tool — for uncomplicated cystitis in otherwise healthy non-pregnant women under 65 with classic symptoms (dysuria + frequency + urgency) and a positive dipstick (leucocytes + nitrites), MSU culture before prescribing is NOT required. The diagnostic accuracy of the clinical presentation + dipstick combination is sufficient to treat empirically. However, the 'test and treat' or 'dipstick + culture' approach remains appropriate for: men, pregnant women, children, patients with recurrent UTI (to identify organisms and sensitivities), immunocompromised patients, those with atypical symptoms, and elderly patients in whom the diagnosis of UTI is more uncertain (atypical presentations are common in elderly — confusion or falls without classic urinary symptoms can represent UTI in this group, but avoid dipsticks in adults over 65, in line with local guidance, because asymptomatic bacteriuria is common). NICE NG109 advises considering local resistance data before prescribing trimethoprim empirically; follow the local antimicrobial guideline.

Bladder pain syndrome (interstitial cystitis) is a diagnosis of exclusion. Suspect it when dysuria, frequency, urgency or bladder-related pelvic pain persist and urine cultures are repeatedly negative. Avoid repeated antibiotic courses when cultures are negative. Before attributing symptoms to bladder pain syndrome, assess for haematuria, pelvic pathology, vaginal causes and red flags, and refer according to the local urology/gynaecology pathway.

The NICE NG12 haematuria referral rule is one of the most important cancer safety-netting rules in primary care — it is frequently violated by attributing haematuria to UTI and not following up after treatment. The correct approach when a patient presents with dysuria AND macroscopic haematuria: (1) check for UTI and treat if confirmed; (2) if there is no UTI, refer on the suspected cancer pathway now (aged 45+); (3) if there was a UTI, confirm the haematuria has cleared after treatment and refer if it persists or recurs (NICE NG12). Bladder cancer can co-present with UTI, and treating the infection does not treat the cancer. A patient who had haematuria with a 'UTI' that appeared to resolve should still be referred if they had not had a urology assessment. GPs should have a system for checking that suspected cancer referrals for haematuria are not inadvertently dropped when haematuria 'resolves' with antibiotics.

Aciclovir for first-episode genital herpes has several important clinical nuances that GPs should know: (1) it must be started within 5 days of lesion onset to be effective (after this, viral replication has largely ceased and antiviral treatment has minimal benefit on the current episode); (2) the antiviral reduces the duration and severity of the episode but does not affect the establishment of latency in the sacral ganglia (herpes will likely recur); (3) patients should be counselled that they will have lifelong HSV infection that can reactivate; (4) suppressive therapy (regimen per current BASHH/GUM protocol) is available for patients with frequent recurrences (≥6/year) and reduces recurrence frequency — this is a GUM clinic discussion; (5) asymptomatic shedding (when the virus is infectious without any visible lesions) occurs intermittently and is responsible for much HSV transmission between sexual partners. GUM referral after the first episode is important to ensure appropriate counselling, partner testing, and long-term management planning.

NICE NG110 (2018) sets a 14-day course for acute bacterial prostatitis followed by review, extending to 28 days only if symptoms persist, because antibiotic penetration into the prostate is poor (blood-prostate barrier) and undertreatment risks relapse and chronic bacterial prostatitis. Ciprofloxacin has the best prostate tissue penetration of available oral antibiotics (lipophilic — crosses the blood-prostate barrier effectively). The clinical monitoring during the course: if the patient is not improving within 48 hours or is worsening, reconsider the diagnosis (prostatic abscess — requires USS/MRI + drainage) or antibiotic choice (culture sensitivity — if organism resistant to ciprofloxacin, switch based on culture). Transrectal ultrasonography (TRUS) is indicated if there is no improvement at 1 week of appropriate antibiotics — a prostatic abscess requires surgical drainage (transperineal or transrectal).

The genital herpes disclosure dilemma is one of the most sensitive psychosocial aspects of managing first-episode HSV — patients often struggle with the question of when and how to inform sexual partners, and some experience significant shame, anxiety about future relationships, and fear of rejection. Proactive, empathetic GP counselling at the first HSV consultation significantly improves patient outcomes. Key messages: HSV is extremely common; most people with genital herpes do not know they have it (majority of acquisition is from asymptomatic shedding by a partner who did not know they were infected); having genital herpes does not mean you or your partner has been unfaithful (the infection can be dormant for years before first presentation); the infection is manageable with suppressive treatment; and long-term relationships with HSV-positive partners are possible with appropriate precautions. GUM referral provides specialist counselling support beyond what can be delivered in a primary care consultation.

Routine test-of-cure culture and renal ultrasound are not required after an uncomplicated, clinically improving episode of pyelonephritis (NICE NG111). Reassess if symptoms worsen or do not improve within 48 hours, review culture results and change treatment if the organism is resistant. Investigate (ultrasound/urology) if obstruction or stone is suspected, infection is recurrent or atypical, there is persistent haematuria or renal impairment, or there is no clinical improvement within 48 hours. Repeat culture is appropriate in pregnancy, with persistent symptoms or recurrence, or when local policy requires it.